Sporadic excesses of unintegrated HIV DNA can occur in HIV+ patients on HAART Una O’Doherty University of Pennsylvania.

Slides:



Advertisements
Similar presentations
Antiretroviral Drug Resistance
Advertisements

Effect of intensification of long-term highly active antiretroviral therapy (HAART) with raltegravir on proviral HIV-1 DNA in blood and gut associated.
T follicular helper cells in HIV infection
New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Measuring the latent HIV Reservoir
Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
Evaluating residual HIV reservoirs Background or why is this important? What can be measured? Where should we measure it? Conclusions.
Gag-positive reservoir cells can be identified by a new technique and can be cleared by CTL ? Una O’Doherty June 29, 2013.
The role of HIV infection and Co-infections in Serious Non-AIDS Events Peter W. Hunt, M.D Associate Professor of Medicine, UCSF.
Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
Journal Club Alcohol and Health: Current Evidence September–October 2006.
High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection Abstract.
Journal Club Alcohol and Health: Current Evidence January-February 2006.
EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.
2014 “Towards an HIV Cure” symposium Melbourne A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-nai ̈ ve individuals.
Measuring the latent HIV Reservoir
David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Viruses.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
Latent infection and cellular reservoirs
Estrogen blocks HIV re-emergence from latency and points to gender- specific differences in HIV reservoirs Jonathan Karn International AIDS Society Hammer.
Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution.
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.
Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.
Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere,
HIV Cellular Pathogenesis III
Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens Giron, LB; Tenore, S; Gabriel, R; Janini,
Characterization of persistent HIV-1 in a broad spectrum of CD4 + T-cells isolated from peripheral blood, bone marrow, lymphoid tissue and gut associated.
Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
Measuring the HIV reservoirs: new and improved methods Sarah Palmer Westmead Millennium Institute for Medical Research University of Sydney.
Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,
Effect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir IAS HIV RESERVOIRS WORKSHOP, 16 & 17 JULY 2010, VIENNA.
Yerkes National Primate Research Center
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display The Steps in HIV Replication Slide number 1 (1) Viral.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
Learning About an HIV Cure by Doing Studies in HIV+ Subjects Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University.
Effect of antiviral use on the emergence of resistance to nucleoside analogs in Herpes Simplex Virus, Type 1 Marc Lipsitch, Bruce Levin, Rustom Antia,
Lessons Learned from Transient Remission Cases: Clues to Biomarkers of HIV Rebound Katherine Luzuriaga, MD University of Massachusetts.
Mathias Lichterfeld, M.D., Ph.D. Massachusetts General Hospital An intrinsic inhibitor of p-TEFb and HIV-1 transcriptional elongation in CD4 T cells from.
What are possible biomarkers for cure-related interventions ? Lars Ostergaard, MD, Ph.D., DMSc Prof/Head Dept of infectious diseases Aarhus.
Title Box. “Towards an HIV Cure”: Presentation Outline -Why do we need a cure? -Is a cure feasible and what type of cure can we reach? -Why does HAART.
IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.
Copyright © 2007 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Resistance to the HIV-Integrase Inhibitor Raltegravir: Analysis.
HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.
The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,
Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Update on HIV Cure Research FORMATTED:
Immune reconstitution Anjie Zhen, PhD
2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.
Cellular immune control of Human Immunodeficiency Virus (HIV) Dr. Ali Jalil Ali College of pharmacy.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection by Thor A. Wagner, Sherry McLaughlin, Kavita Garg, Charles.
Barriers to HIV Cure Janet M. Siliciano, PhD
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
Prolonged HIV-1 Remission and Viral Rebound in an Individual Treated During Hyperacute Infection Timothy Henrich, Hiroyu Hatano, Alison Hill, Oliver Bacon,
A HIGHER FRACTION OF DRUG RESISTANT PROVIRUSES EXPRESS UNSPLICED HIV RNA DURING ART COMPARED TO THE ARCHIVAL WILD-TYPE PROVIRUSES THAT COMPRISE THE HIV-1.
HIV Cure: Current Status and Future Perspectives
Feedback meeting September 2017
Volume 2, Issue 8, Pages (August 2015)
HEATHER Feedback Meeting
The block-and-lock approach
What Integration Sites Tell Us about HIV Persistence
Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection  Lin Shen, MD, Robert F. Siliciano,
Contribution of naïve CD4+ T cells to the intact HIV reservoir
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

Sporadic excesses of unintegrated HIV DNA can occur in HIV+ patients on HAART Una O’Doherty University of Pennsylvania

How are reservoirs of HIV maintained in patients on HAART? 1.Resting T cells are latently infected early and persist 2.Very low levels of ongoing replication occur

Unclear if ongoing replication may occur on HAART Against: –viral evolution studies –Intensification studies However: –Low levels of ongoing replication –Sporadic ongoing replication –Only occur in a subset of HAART patients –Evidence in: HIV DNA in aCD4 (Chun et al 2005) 2-LTR with Raltegravir (Buzon et al 2010) Half-life of unintegrated HIV DNA (Koelsch et al 2008 and Chomont et al 2009) Thus, we need a sensitive method to detect viral replication.

provirus PIC provirus PIC HAART Effective HAART should clear unintegrated HIV DNA T 1/2 of Pre-integrated HIV DNA = 3 days

Generation of the Integration Standard (IS) cell line The standard contains the following: –Only integrated HIV DNA –Multipe integration sites to reflect the high level of diversity of integration site selection during natural infection

Repetitive sampling of Integration standard

Validation of our assay

Validation of integration assay

Confidence interval: ratio of total HIV DNA/integrated with our integration standard

An excess of unintegrated HIV DNA occurs off HAART

An excess of unintegrated HIV DNA occurs in Elite Suppressors

An excess of unintegrated HIV DNA occurs in some patients on HAART

One patient without an excess of unintegrated HIV DNA on HAART

Sporadic excess of unintegrated HIV DNA occur on HAART

Sporadic excesses of unintegrated HIV DNA on HAART

Conclusions A fraction of patients on HAART have a clear excess of unintegrated HIV DNA Longitudinal study suggests excess may occur sporadically An excess of unintegrated DNA may provide a surrogate marker for ongoing replication

Acknowledgements My lab –Angela Mexas –Erin Graf –Jianqing Yu –Luis Agosto –Matthew Pace Funding –Merck, NIH NIH NIAID –Stephen Migueles –Mark Connors –Tae-Wook Chun Penn –Robert Gross –Ian Frank –Bruce Levine –Avinash Bhandoola Merck –Daria Hazuda

Reproducibility total/integrated HIV

Longitudinal samples suggest sporadic excess may occur

Sporadic excess of unintegrated HIV DNA occur on HAART

Sporadic blips of unintegrated HIV DNA on HAART

Overtime total HIV DNA approaches integrated HIV DNA on HAART Koelsch JID 2008

The level of unintegrated HIV DNA decreases with HAART Copies per cell

An excess of unintegrated HIV DNA occurs in some patients on HAART Patient number Copies per cell Total HIV (SST)Integrated HIV 11*

The half-life of unintegrated HIV DNA is ~ 3 days in rCD4+T cells treated

An excess of unintegrated HIV DNA occurs in some patients on HAART

Assay of HIV integration

Unclear if ongoing replication may occur on HAART Against –viral evolution studies –Intensification studies However: –Low levels of ongoing replication may occur without detectable evolution –Replication may occur sporadically –Replication may occur in a subset of patients on HAART –Buzon et al 2010, Koelsch et al 2008 and Chomont et al 2009 Thus, we need a sensitive method to detect viral replication.

Validation of our assay